The blood-brain barrier and treatment of lysosomal storage diseases

International Congress Series

Volumn 1277, Issue , 2005, Pages 19-31

  Aerts, J M ^a   van Breemen, M J ^a   Bussink, A P ^a   Brinkman, J ^a   Hollak, C E M ^a   Langeveld, M ^a   Linthorst, G E ^a   Vedder, A C ^a   de Fost, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Blood brain barrier; Lysosome; Neuropathology; Storage; Therapy

Indexed keywords

EID: 33646568503     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2005.02.009     Document Type: Article

References (43)

1. De Duve C., et al. Tissue fractionation studies. Intracellular distribution patterns of enzymes in rat liver tissue. Biochem. J. 60 (1955) 604-617
2. Peters C., and von Figura K. Biogenesis of lysosomal membranes. FEBS Lett. 346 (1994) 108-114
3. Kornfeld S., and Mellman I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5 (1989) 483-525
4. Aerts J.M., et al. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J. Inherit. Metab. Dis. 16 (1993) 288-291
5. Renkema G.H., et al. Synthesis, sorting and processing into distinct isoforms of human macrophage chitotriosidase. Eur. J. Biochem. 244 (1997) 279-285
6. Rijnboutt S., et al. Mannose-6-phosphate independent membrane association and maturation of cathepsin D, glucocerebrosidase and sphingolipid-activating protein in HepG2 cells. J. Biol. Chem. 266 (1991) 4862-4868
7. Neufeld E.F. Lysosomal storage disorders. Annu. Rev. Biochem. 60 (1991) 257-280
8. Gieselmann V. Lysosomal storage diseases. Biochim. Biophys. Acta 1270 (1995) 103-136
9. Futerman A.H., and van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev., Mol. Cell Biol. 5 (2004) 554-565
10. Poorthuis B.J.H.M., et al. The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 105 (1999) 151-156
11. Meikle P.F., et al. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
12. Peltonen L. Molecular background of Finnish disease heritage. Ann. Med. 29 (1997) 553-556
13. Barranger J.A., and Ginns E.I. Glycosylceramide lipidosis: Gaucher disease. The metabolic basis of inherited disease. 6th edn. (1989), McGraw-Hill 1677-1698
14. Beutler E., and Grabowski G. Gaucher disease. The metabolic basis and molecular basis of inherited disease. 8th edn. (2001), McGraw-Hill, New York 3635-3668
15. Brady R.O., et al. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45 (1966) 1112-1115
16. Patrick A.D. A deficiency of glucocerebrosidase in Gaucher's disease. Biochem. J. 97 (1965) 17c-18c
17. Van Weely S., et al. Role of pH in determining the cell-type specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J. Clin. Invest. 91 (1993) 1167-1175
18. Aerts J.M., et al. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J. Inherit. Metab. Dis. 16 (1993) 288-291
19. Cox T.M., and Schofield J.P. Gaucher's disease: clinical features and natural history. Bailliere's Clin. Haematol. 10 (1997) 657-689
20. Lachmann R.H., et al. Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 97 (2004) 199-204
21. Aerts J.M., and Hollak C.E. Plasma and metabolic abnormalities in Gaucher's disease. Bailliere's Clin. Haematol. 10 (1997) 691-709
22. Cox T.M. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J. Inherit. Metab. Dis. 24 Suppl. 2 (2001) 106-121
23. Boot R.G., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103 (2004) 33-39
24. Boven L.A., et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 122 (2004) 359-369
25. Moran M.T., et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96 (2000) 1969-1978
26. Ringden O., et al. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 56 (1995) 864-870
27. Richter J., and Karlsson S. Clinical gene therapy in hematology: past and future. Int. J. Hematol. 73 (2001) 162-169
28. Barranger J.A., and O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 24 Suppl. 2 (2001) 89-96
29. Linehan S.A., et al. Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs. In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia and mesanglial cells, but not dendritic cells. J. Exp. Med. 189 (1999) 1961-1972
30. Barton N.W., et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1913-1916
31. Grabowski G.A., et al. Enzyme therapy in type 1 Gaucher disease: comparitive efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122 (1995) 33-39
32. Eriksson A. Remaining problems in the management of patient with Gaucher disease. J. Inherit. Metab. Dis. 24 Suppl. 2 (2001) 122-126
33. Platt F.M., et al. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269 (1994) 8362-8365
34. Cox T., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 355 (2000) 1481-1485
35. Cox T.M., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26 (2003) 513-526
36. Andersson U., et al. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in mouse model of Sandhoff disease. Neurobiol. Dis. 16 (2004) 506-515
37. Overkleeft H.S., et al. Generation of specific deoxynijirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273 (1998) 26522-26527
38. Abe A., et al. Agents for the treatment of glycosphingolipid storage disorders. Curr. Drug Metab. 2 (2001) 331-338
39. Butters T.D., Dwek R.A., and Platt F.M. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Adv. Exp. Med. Biol. 535 (2003) 219-226
40. Shen C., et al. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. Int. Immunopharmacol. 4 (2004) 939-951
41. Wu Y.P., and Proia R.L. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8425-8430
42. Proia R.L., and Wu Y.P. Blood to brain to the rescue. J. Clin. Invest. 113 (2004) 1108-1110
43. Myerowitz R., et al. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet. 11 (2002) 1343-1350